Centrum Medyczne Intercor Sp. z o.o. — Clinical Trial Site

39 Registered trials

14 Currently recruiting

Organisation

Centrum Medyczne Intercor Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100043433

Address

Ul. Kasztanowa 57, 85-605, Poland

Departments

3018:Cardiology
Badania Kliniczne
Centrum Medyczne „INTERCOR”
Centrum Medyczne Intercor Sp. z o.o.
Chronic pain
Endocrinology
INTERCOR
n/a
NA
Outpatient clinic
Poradnia Endokrynologiczno-Diabetologiczna
Poradnie Specjalistyczne
psychiatry
Specialist clinics
Spółka Lekarzy "Intercor"
The Company of Doctors "Intercor" Ltd.

Clinical trials at this site (39)

Search interface

LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended

2023-506359-68-00 Active Proliferative Lupus Nephritis 5 2022-04-08
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly… Ended

2023-508924-36-00 Type 2 diabetes mellitus (T2DM) 5 2024-08-20
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Mixed Dyslipidemia 4 2024-07-04
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505902-40-00 Heart Failure with Preserved Ejection Fraction 4 2023-03-28
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromeg… Ended

2024-511924-15-00 Acromegaly 5 2022-04-29
Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA… Ended

2023-506961-74-00 Non-alcoholic steatohepatitis (NASH) 4 2021-08-31
Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Ended

2024-511925-71-00 Acromegaly 5 2021-08-05